Holen Sie sich die Stockscreener-App
17.77
2.36%
-0.43
Vorhandelsmarkt:
17.96
0.19
+1.07%
Schlusskurs vom Vortag:
$18.20
Offen:
$18.12
24-Stunden-Volumen:
954.93K
Relative Volume:
0.59
Marktkapitalisierung:
$2.07B
Einnahmen:
$674.41M
Nettoeinkommen (Verlust:
$-173.05M
KGV:
-11.58
EPS:
-1.5343
Netto-Cashflow:
$-48.07M
1W Leistung:
+2.24%
1M Leistung:
+11.48%
6M Leistung:
+56.43%
1J Leistung:
+50.85%
1-Tages-Spanne:
$17.48
$18.61
1-Wochen-Bereich:
$16.78
$18.61
52-Wochen-Spanne:
$9.82
$21.45
Novocure Ltd Stock (NVCR) Company Profile
Firmenname
Novocure Ltd
Sektor
Branche
Telefon
44 (0)15 3475 6700
Adresse
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
17.77 | 2.12B | 674.41M | -173.05M | -48.07M | -1.5343 |
ABT
Abbott Laboratories
|
114.14 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
327.70 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.30 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.37 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.83 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-12-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Eingeleitet | SVB Securities | Outperform |
| 2023-07-31 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Hochstufung | Wedbush | Underperform → Neutral |
| 2023-05-16 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Bestätigt | H.C. Wainwright | Buy |
| 2022-11-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-08 | Eingeleitet | Loop Capital | Buy |
| 2022-02-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2022-01-03 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-14 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-01-25 | Bestätigt | Piper Sandler | Overweight |
| 2020-09-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-09-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Herabstufung | Truist | Buy → Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Perform |
| 2020-05-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Hochstufung | SunTrust | Hold → Buy |
| 2019-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2018-11-02 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2018-04-18 | Bestätigt | Mizuho | Buy |
| 2018-02-23 | Bestätigt | Mizuho | Buy |
| 2017-05-24 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Bestätigt | Wedbush | Outperform |
| 2016-01-19 | Eingeleitet | Barclays | Underweight |
| 2015-12-02 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
Novocure | 8-K: Current report - Moomoo
What’s Behind NovoCure (NVCR) Shares Climbing Today? - simplywall.st
NVCR|Novocure Ltd|Price:18.200|Chg%:+0.960 - TradingKey
NVCR Q2 2026 Earnings: Loss Narrower Than Expected; Shares Slip 0.82Earnings Preview - Vinanet
Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet - Yahoo Finance
NovoCure (NVCR) Is Up 8.5% After Advancing Tumor Treating Fields Pipeline And Trials ProgressHas The Bull Case Changed? - simplywall.st
Sei Investments Co. Buys 89,839 Shares of NovoCure Limited $NVCR - MarketBeat
First Trust Advisors LP Invests $1.03 Million in NovoCure Limited $NVCR - marketbeat.com
NovoCure (NVDA) Following TTFields Optimism And FDA Approval Hopes Looks Undervalued - simplywall.st
NovoCure (NASDAQ:NVCR) Rating Increased to Buy at Wall Street Zen - MarketBeat
Novocure Ltd (NVCR) Stock Analysis & Forecast - TradingKey
NovoCure Ltd (038.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Quantinno Capital Management LP Has $27.11 Million Stock Position in NovoCure Limited $NVCR - MarketBeat
Novocure Stock Price Forecast. Should You Buy NVCR? - StockInvest.us
NovoCure (NVCR) Stock Looks Undervalued With Shares Down 90% Over Five Years - simplywall.st
Healthcare of Ontario Pension Plan Trust Fund Sells 201,000 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Novocure Hits Record Revenue & Raises 2026 Outlook - Streetwise Reports
Novocure Ltd (NVCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Novocure Posts Record Q2 Revenue of US$183.6M - Streetwise Reports
Novocure Ltd (NVCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
NovoCure Market Sentiment - Benzinga España
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade - Yahoo Finance Singapore
Novocure Ltd (NVCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Unlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and Prospects - Yahoo! Finance Canada
NovoCure Ltd. (NVCRN) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
NovoCure (NVCR) Is Up 10.9% After Raising 2026 Revenue Outlook and Securing New CE Mark Approval – Has The Bull Case Changed? - simplywall.st
NovoCure Ltd. Revenue Breakdown – FWB:038 - TradingView
NovoCure Ltd. Revenue Breakdown – LSX:A140ML - TradingView
NovoCure Ltd. (NVCRN) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
NovoCure (NVCR) Lifts 2026 Guidance After Record Quarter While Fair Value Debate Builds - Yahoo Finance UK
TradingKey - TradingKey
Novocure Ltd (NVCR) Cash Flow - TradingKey
NovoCure (NVCR) Stock Faces Ongoing Losses As Q2 2026 EPS Narrows To $0.13 Loss - simplywall.st
Novocure Ltd (NVCR) Institutional Confidence - TradingKey
NVCR Maintained by Wedbush -- Price Target Raised to $20.00 - GuruFocus
H.C. Wainwright cuts NovoCure stock price target to $32 on valuation - Investing.com UK
Novocure Is Maintained at Neutral by Wedbush - Moomoo
NovoCure Posts Record Revenue and Raises Guidance, But NVCR Stock Tumbles Over 6% - finance.biggo.com
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding - Benzinga
Form 144 NovoCure Limited For: 24 July By Investing.com - Investing.com Nigeria
NovoCure (NVCR) Stock Soars 28% on Milestone Quarter and Strong Revenue Forecast - Blockonomi
NovoCure (NVCR) Stock Jumps 28% After Record Revenue and Raised Guidance - CoinCentral
NovoCure Q2 2026 slides: profitability in sight, guidance raised By Investing.com - Investing.com Nigeria
NovoCure (NASDAQ:NVCR) Shares Gap Up on Strong Earnings - MarketBeat
Novocure Ltd earnings beat by $0.20, revenue topped estimates - Investing.com Nigeria
Novocure Cash, Cash Equivalents and Short-Term Investments Were $440.6M as of June 30 >NVCR - Moomoo
BR:N2VC34 Stock Latest News - TipRanks
NovoCure (NVCR) Breaks Out on Q2 2026 EarningsOptune Pax Driving Recovery - TradingKey
Finanzdaten der Novocure Ltd-Aktie (NVCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Novocure Ltd-Aktie (NVCR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Leonard Frank X | Chief Executive Officer |
Jun 04 '26 |
Sale |
17.93 |
34,273 |
614,635 |
459,520 |
1.76%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):